1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Research on Short-Lived and Long-Lived Plasma Cells in Humans | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Research on Short-Lived and Long-Lived Plasma Cells in Humans When beginning your next investigator-initiated application, consider the following NIH highlighted topic. The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs).
This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. gov .
Learn how to interpret and use Highlighted Topics . Post Date: September 10, 2025 Expiration Date: September 10, 2027 This topic encourages applications to understand the biology of Short-Lived Plasma Cells (SLPC) and Long-Lived Plasma Cells (LLPC) through characterization of plasma cell phenotypes and function in human health and disease.
The continuous production of antibodies by LLPC is critical for life-long protective humoral immunity because it does not require restimulation with antigen, unlike the requirements to activate memory B cells.
However, LLPC also produce antibodies that: Mediate some autoimmune diseases Promote allergic responses Mediate organ/tissue transplant rejection Limit patient access to organ transplantation via pre-sensitization LLPC cannot be easily depleted by most drugs currently used to deplete B cells.
In contrast, SLPC have reduced survival programming, generally produce lower affinity antibodies, and are susceptible to B cell depletion therapies. LLPC may arise from a subset of SLPC or from distinct differentiation pathways compared to SLPC; although details of the pathways, mediators, and mechanisms of SLPC and LLPC generation remain to be elucidated.
This topic encourages applications that include: Ex vivo analysis of human samples New approach methodologies (NAMs) Computational modeling of plasma cells in human health and disease Central Scientific Contact: National Institute of Allergy and Infectious Diseases (NIAID) This topic will provide foundational information for rational vaccine design to promote Long-Lived Plasma Cells (LLPC) for durable immunity; diminish LLPC or their activity in autoimmune and allergic diseases, and organ transplantation; or redirect plasma cell fate differentiation to the Short-Lived Plasma Cell (SLPC) population.
Examples of research areas associated with protective or pathogenic immune responses in infectious, immune-mediated or allergic diseases include: Identification/characterization of precursor subsets of SLPC or LLPC. Characterization of tissue sites and local factors that promote bone marrow engraftment, differentiation, and persistence or residence at alternative sites, e.g., mucosa.
Effects of host factors (age, microbiome, etc) on SLPC and LLPC differentiation and function. Comparison of antigen types and formats (soluble, membrane bound) promoting LLPC vs SLPC. National Institute on Aging (NIA) Examples of research areas relevant to the National Institute on Aging (NIA): Changes in the biology of plasma cell subpopulations during aging.
Functional impact of aging phenotypes such as cardiac amyloidosis, frailty, and cognitive decline in plasma cell disorders. Geroscience interventions to enhance effective immune response, delay or potentially reverse immune aging in patients with plasma cell disorders. Mulualem E.
Tilahun, D. V. M.
, Ph. D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Office of Research on Women's Health (ORWH) The Office of Autoimmune Disease Research in the Office of Research on Women’s Health (OADR-ORWH) is interested in research focusing on: Understanding the relationship between Short-Lived Plasma Cells (SLPC)and Long-Lived Plasma Cells (LLPC) and how LLPC mediates autoantibody production in pre-clinical autoimmunity and autoimmune disease Study the sex influences in vaccine research utilizing the new approach methodologies (NAMs) and computational modeling of plasma cells in human health and disease.
Accelerating scientific discovery in diagnosis, treatment, prevention, and cures and enhancing health for people with autoimmune disease. This office does not award grants. Applications must be relevant to the objectives of at least one of the participating NIH Institutes and Centers listed in this topic.
Victoria Shanmugam, MBBS, MRCP, FACR, CCD For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Investigator-initiated applications from various institutions, including academic and research institutions. Confirm the full requirements in the official notice before applying.
Applications for Research on Short-Lived and Long-Lived Plasma Cells in Humans are due September 10, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on Short-Lived and Long-Lived Plasma Cells in Humans is funded by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Clinical Research Network on Antimicrobial Resistance (AMR) (RFA-AI-27-005) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). NIAID seeks to continue support for a Clinical Research Network on Antimicrobial Resistance (AMR) to design, implement, and manage clinical research addressing key clinical questions in AMR.
NIAID Career Transition Award (K22) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID) / National Institutes of Health (NIH). This award provides support for investigators transitioning from a mentored postdoctoral research position to an independent faculty position. It aims to bridge the gap between mentored and independent research, with a focus on immunology and infectious diseases.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
OMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read articleNIH's June 1 omnibus reset added Direct-to-Phase II to the STTR program for the first time. The change compresses university spinouts' funding timeline from three years to fifteen months, but the 30% research-institution subaward, feasibility-evidence rules, and IP licensing mechanics are not yet sorted at most universities.
Read articleNIH committed $402 million across 601 multiyear-funded grants in the first eight months of FY 2026 — more than four times the pace of two years ago. The mechanism front-loads obligations into a single fiscal year, leaving less budget for new project starts and squeezing FY 2026 success rates. What researchers and institutions should be doing now.
Read article